Research

KU Eye physicians performing cutting-edge, basic, clinical and applied research in ophthalmology and vision science

Eye

Current Research

Faculty as Principle Investigator

Ranibizumab for Edema of the macula in Diabetes:  Protocol 3 with High Dose -- the READ 3 Study

Principle Investigator: John Sutphin, MD

Sub-investigator: Thomas Whittaker, MD

INTACS Prescription Inserts For Keratoconus--Humanitarian Use Device

Principle Investigator: John Sutphin, MD

The Association of Cytokines in the Two Clinical Subtypes of Ophthalmic Graves' Disease

Principle Investigator: Jason Sokol, MD

Effect of ocular steroid treatment for diabetic macular edema after failure of treatment with Vascular Endothelial Growth Factor Inhibitors

Principle Investigator: Jennifer Spiegel, MD

Faculty as Sub-Investigator

A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivation Therapy

Principle Investigator: Jeff Holzbeierlein, MD

Sub-investigator: Miranda Bishara, MD

Efficacy of Prednisone in the Treatment of Ocular MyasthEnia (EPITOME)

Principle Investigator: Richard Barohn, MD

Sub-investigator: Thomas Whittaker, MD

A Phase 2 Study of SAR245409 in Patients with Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, or diffuse large B-cell lymphoma

Principle Investigator: Richard Barohn, MD

Sub-investigator: Miranda Bishara, MD; Dirck Dekeyser, OD

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis

Principle Investigator: Sharon Lynch, MD

Sub-investigator: Thomas Whittaker, MD

Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients with relapsing-remitting multiple sclerosis

Principle Investigator: Sharon Lynch, MD

Sub-investigator: Thomas Whittaker, MD

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 1.25 mg FTY720 Administered Orally Daily Versus Placebo in Patients with Primary Progressive Multiple Sclerosis

Principle Investigator: Sharon Lynch, MD

Sub-investigator: Thomas Whittaker, MD; Miranda Bishara, MD; Dirck Dekeyser, OD

A Phase 2 Randomized, Double-Bline, Placebo-Controlled Study of GS-5885, GS-9451, Tegbuvir and Ribavarin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subjects with Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

Principle Investigator: Ryan Taylor, MD

Sub-investigator: Thomas Whittaker, MD

Last modified: Aug 20, 2013
ID=x8292